DrugPatentWatch Database Preview
Drugs in Development Information for GLPG1205
» See Plans and Pricing
What is the drug development status for GLPG1205?
GLPG1205 is an investigational drug.
There have been 6 clinical trials for GLPG1205.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.
The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for GLPG1205
| US Patents | 2 |
| International Patents | 42 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-12-01) |
| Vendors | 4 |
Recent Clinical Trials for GLPG1205
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects | Galapagos NV | Phase 1 |
| A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF) | Galapagos NV | Phase 2 |
| A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects | Galapagos NV | Phase 1 |
Clinical Trial Summary for GLPG1205
Top disease conditions for GLPG1205
Top clinical trial sponsors for GLPG1205
US Patents for GLPG1205
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GLPG1205 | Start Trial | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | Galapagos NV (Mechelen, BE) | Start Trial |
| GLPG1205 | Start Trial | Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (Mechelen, BE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GLPG1205
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GLPG1205 | Argentina | AR089284 | 2031-12-22 | Start Trial |
| GLPG1205 | Australia | AU2012357067 | 2031-12-22 | Start Trial |
| GLPG1205 | Brazil | BR112014015142 | 2031-12-22 | Start Trial |
| GLPG1205 | Canada | CA2859578 | 2031-12-22 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
